Imodium Rapid

Loperamide Hydrochloride, the active ingredient in Imodium Rapid, is an antidiarrheal presented as a 2 mg oral tablet for oral use. It treats acute nonspecific diarrhea, chronic diarrhea associated with inflammatory bowel disease, and travelers' diarrhea in adults and children as appropriate.

GNH USA supplies Imodium Rapid as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium Rapid (loperamide) is used to manage diarrheal conditions by reducing intestinal motility.

Acute nonspecific diarrhea: provides symptomatic relief by decreasing stool frequency and liquidity. Chronic diarrhea associated with inflammatory bowel disease: helps control stool output when other therapies are insufficient. Travelers' diarrhea: reduces symptoms and allows continuation of travel activities.

Common side effects are generally mild and related to reduced gut motility.

Common Side Effects: - Constipation: reduced bowel movements leading to hard stools. - Abdominal cramps: mild cramping or discomfort. - Nausea: occasional feeling of sickness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe constipation or bowel obstruction: risk of impaction requiring medical attention. - Toxic megacolon: rare but serious colonic dilation. - Cardiac arrhythmias: rare QT prolongation leading to irregular heartbeat.

Before using Imodium Rapid, consider the following safety measures.

Dosage adjustment: use lower doses in patients with hepatic impairment. Dehydration risk: ensure adequate fluid intake while using the product. Underlying infection: avoid if diarrhea is caused by invasive bacterial infection without medical supervision. Pediatric use: follow pediatric dosing guidelines; not recommended for children under 2 years. Pregnancy and lactation: consult a healthcare professional; safety not established. Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Loperamide may interact with other medicines; review the following categories.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase loperamide plasma levels. - P‑glycoprotein inhibitors (e.g., quinidine, ritonavir): can raise systemic exposure. - Opioid analgesics: additive central opioid effects may increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance anticholinergic burden, causing constipation. - Antidiarrheal agents (e.g., bismuth subsalicylate): overlapping effects may lead to excessive slowing of gut motility. - CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation if systemic absorption occurs.